Research Article
Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry
Table 4
Clinical outcome at longest follow-up.
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Randomized Impella arm ° Data at longest follow up available in the intention-to-treat population § Composite rate of intra- and postprocedural major adverse events (MAEs) at discharge or 30-day follow-up, whichever was longer. The composite primary end point components included all-cause death, Q-wave or non–Q wave MI, stroke, or transient ischemic attack, any repeat revascularization procedure, need for a cardiac or a vascular operation, acute renal insufficiency, severe intraprocedural hypotension requiring therapy, cardiopulmonary resuscitation or ventricular tachycardia requiring cardioversion, aortic insufficiency, and angiographic failure of PCI. † Includes PCI or CABG revascularization. MACCE=major adverse cardiac and cerebrovascular events; PCI= percutaneous coronary intervention; CABG=coronary artery bypass grafting; AMI=acute myocardial infarction |